Advances in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia

Matched sibling donor (MSD) or matched unrelated donor (MUD) hematopoietic stem cell transplantation is the frontline therapy for severe aplastic anemia. When MSD or MUD is not available, then intensive immunosuppressive therapy (IST) is indicated. However, IST has a high relapse rate due to lack of response. Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) has been developing so rapidly that they could now replace the transplantation from identical siblings with similar effcacy. The application of Haplo-HSCT terminate the era of donor shortage and bring beneft to the patients. This review will focus on the progress of the therapeutic effect of Haplo-HSCT in the treatment of SAA.